IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75."

New Caregiver Resource Showcases Expert Contributions and Reinforces IGC Pharma's Leadership in Alzheimer's Innovation

POTOMAC, MD / ACCESS Newswire / December 2, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced the publication of "Caring for a Loved One with Alzheimer's Disease: First Hand Experiences," a comprehensive caregiver-focused book sponsored by IGC Pharma and authored by several of the world's leading experts in neuropsychology and dementia care.

The book written by renowned clinical neuropsychologists Dr. Juan Carlos Arango-Lasprilla and Dr. Sandra Báez, alongside co-authors Dr. Valeria Villamizar, and Dr. Natalia Valech presents science-based education, practical strategies, and real-life narratives from families impacted by Alzheimer's disease. Dr. Sandra Báez serves as an external advisor to IGC Pharma, contributing her expertise to the company's long-term strategy to improve the understanding, treatment, and lived experience of Alzheimer's disease worldwide.

"This book represents an essential contribution to the global Alzheimer's community," said Ram Mukunda, CEO of IGC Pharma. "Our diverse pipeline of candidates, including IGC-AD1, currently advancing through the Phase 2 CALMA trial for agitation in Alzheimer's dementia, demonstrates how we are translating scientific innovation into potential treatments, and this book complements those efforts by supporting broader community engagement and awareness as we move toward commercialization."

A Comprehensive Guide Supporting Families and Caregivers

The book is organized into two major sections:

1. Educational Chapters on Alzheimer's Disease

Covering topics such as:

• What Alzheimer's disease is and how it progresses

• Causes, risk factors, and protective factors

• Diagnosis and clinical evaluation

• Myths and misconceptions

• The role of the caregiver and the family

• Caregiver mental and physical health

• Planning for the future and long-term care

• Available pharmacological and non-pharmacological treatments

These chapters provide scientifically grounded guidance for caregivers seeking clarity, validation, and practical support.

2. First-Person Caregiver Stories

The second half of the book contains real-life testimonies of families who have cared for loved ones with Alzheimer's disease. These narratives highlight:

• Emotional challenges and resilience

• Communication difficulties and behavioral symptoms

• The importance of social support

• The value of meaningful connections, even in advanced stages

Each story offers reflection, empathy, and concrete lessons for navigating the caregiving journey.

Strategic Alignment with IGC Pharma's Mission

The publication reinforces IGC Pharma's commitment to addressing Alzheimer's disease from every angle, scientific, social, and therapeutic. The company is currently advancing IGC-AD1, a cannabinoid-based investigational therapy in Phase 2 trials for agitation in Alzheimer's dementia, while simultaneously developing AI-driven tools and additional therapeutic programs targeting amyloid plaques, tau pathology, neuroinflammation, and mitochondrial dysfunction.

By supporting educational resources such as this book, IGC Pharma not only strengthens community awareness but also enhances its long-term strategic position as a leader in Alzheimer's therapeutic innovation and patient-centered solutions.

About the Authors (External Advisors to IGC Pharma)

• Dr. Juan Carlos Arango-Lasprilla - A globally recognized neuropsychologist, author of 24 books and 450+ scientific articles.

• Dr. Sandra Báez - Associate Professor at Los Andes University (Colombia) and award-winning researcher in social cognition and neuropsychology and 120+ scientific articles.

• Natalia Valech - Neuropsychologist specializing in psychogerontology with clinical experience across Spain, Chile, and Canada.

• Valeria Villamizar - Psychologist focused on cognition, behavior, and applied neuroscience in Alzheimer's care.

The book is now available for free download. To access it, click here for the English edition or here for the Spanish edition. We encourage caregivers, families, clinicians, and community organizations to share these resources widely to support all those affected by Alzheimer's disease.

About IGC Pharma (dba IGC):

IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With a complete patent portfolio and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.

Forward-Looking Statements:

This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

Contact Information:

Rosalyn Christian / John Nesbett

IMS Investor Relations

igc@imsinvestorrelations.com

(203) 972-9200

SOURCE: IGC Pharma, Inc.

View the original press release on ACCESS Newswire

POTOMAC, MD / ACCESS Newswire / November 25, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced advances in MINT-AD, the Multimodal Interpretable Transformer for Alzheimer's. Leveraging data from the Health and Retirement Study (HRS) International Family of Studies, IGC Pharma aims to identify unknown socioeconomic risk factors and their interactions influencing aging and cognitive decline. This initiative is part of IGC Pharma's broader mission to revolutionize Alzheimer's treatment with precision medicine and AI-driven insights.

Among the datasets used in MINT-AD training, IGC Pharma is leveraging 14 large-scale longitudinal aging and cognition studies spanning the USA, Africa, Mexico, China, Costa Rica, Puerto Rico, Chile, Brazil, England, Thailand, Indonesia, India, and Korea, all adhering to HRS protocol. This approach enables AI to identify critical socioeconomic factors contributing to early cognitive decline across populations with diverse sociocultural contexts, offering a new way to predict, stratify, and intervene before Alzheimer's takes hold.

"Understanding the socioeconomic factors that contribute to cognitive decline is critical to advancing more effective Alzheimer's treatments, at a time when it is increasingly critical to improve healthcare strategies for the rapidly aging population," said Ram Mukunda, CEO of IGC Pharma. "By leveraging AI and global longitudinal datasets, we are identifying hidden relationships between socioeconomic factors and cognitive health, allowing us to develop personalized non-pharmacological interventions that could transform public health policies and improve clinical outcomes. This research complements our ongoing IGC-AD1 clinical trials, where we are developing targeted therapies for both agitation in Alzheimer's dementia and potential disease-modifying treatments."

This project is structured around three core objectives: Risk Stratification, using AI models to classify populations by Alzheimer's risk levels for targeted prevention; Early Detection of Cognitive Decline, using historical socioeconomic, health, and psychosocial data to enable timely interventions; and Modeling Disease Progression Under Different Interventions, simulating how modifiable social factors impact Alzheimer's progression to inform public health strategies and optimize treatment approaches.

Over 400 million individuals are projected to have Alzheimer's Disease pathology and are at risk for the disease, increasing the demand for effective solutions. While new treatments are emerging, current medications follow a one-size-fits-all approach that fails to account for individual differences in genetics, diet, environment, and lifestyle factors that influence disease progression and treatment response. IGC Pharma's AI models are designed to change that by identifying at-risk populations, predicting cognitive decline years in advance of onset, and modeling disease progression under various intervention scenarios.

About IGC Pharma (dba IGC):

IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With more than 30 patent filings, 12 patents granted and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.

Forward-Looking Statements:

This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

Contact Information:

Rosalyn Christian / John Nesbett

IMS Investor Relations

igc@imsinvestorrelations.com

(203) 972-9200

SOURCE: IGC Pharma, Inc.

View the original press release on ACCESS Newswire

Company Accelerates Phase 2 Alzheimer's Program and Gains National Institute on Aging (NIA) Recognition for AI Leadership

POTOMAC, MARYLAND / ACCESS Newswire / November 17, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced financial results for the quarter ended September 30, 2025 (Second Quarter of Fiscal Year 2026) and provided a compelling update on its accelerated clinical and strategic progress.

Q2 FY 2026 Strategic and Operational Highlights

• Strategic Financial Discipline: Executed a strategic divestiture of a non-core manufacturing facility for $2.7 million (fair value, September 29, 2025), booking a non-cash profit of approximately $1.1 million, while eliminating $600 thousand in annual operating expenses. This transaction secures long-term preferential supply rights of future sale proceeds, materially enhancing financial flexibility.

• Clinical Momentum Reaches Midpoint: Achieved more than 50% patient enrollment in the Phase 2 CALMA trial of IGC-AD1 for agitation associated with Alzheimer's dementia (announced September 22, 2025), significantly advancing the timeline to trial completion.

• AI Leadership Recognized: Received a prestigious special award from the National Institute on Aging (NIA) for excellence in code clarity, reproducibility, and usability in Alzheimer's detection, validating IGC's AI-first approach (September 9, 2025).

• Expanding Pipeline Scope: Reported encouraging preclinical data for IGC-M3, a small-molecule candidate designed to hit multiple Alzheimer's disease pathways, including amyloid aggregation, mitochondrial dysfunction, and neuroinflammation (August 12, 2025).

"This quarter reflects the disciplined execution of our dual strategy in clinical trials and artificial intelligence, positioning IGC to create meaningful shareholder value," said Ram Mukunda, CEO of IGC Pharma. "We've accelerated our lead Alzheimer's program past the 50% enrollment mark, demonstrating our operational focus. Simultaneously, we converted a previously cash-negative manufacturing facility into a favorable contract that strengthens our balance sheet. The NIA award underscores that our unique AI platform is not just a concept, but a recognized tool accelerating Alzheimer's diagnostics. We are confident this progress sets the stage for rapid advancement in the quarters ahead."

Operational & Pipeline Progress in Detail:

• Phase 2 CALMA Trial Expansion: The ongoing Phase 2 CALMA trial for IGC-AD1 was strategically expanded to new international and domestic sites, including Island Health's Royal Jubilee Hospital in Victoria, British Columbia, Canada, and Lynn Health Science Institute (LHSI) in Oklahoma City, Oklahoma. This expansion is designed to accelerate the remaining enrollment and enhance patient diversity.

• Patent Protection Secured: The Company received a Notice of Allowance from the USPTO for its patent application IGC510 (US 17/613,909), a proprietary method for treating individuals suffering from stammering, stuttering, or Tourette's syndrome.

Financial Summary:

Note on Revenue: Revenue for the quarter was approximately $191 thousand, a decrease of 54% from the prior year, primarily due to the planned transition period associated with the disposition of the Company's Vancouver manufacturing facility and the focused shift toward advancing the core pharmaceutical pipeline. This planned transition pursuant to the new favorable contract is expected to yield long-term financial benefits.

IGC expects continued strong momentum heading into the second half of fiscal 2026, with key strategic priorities focused on pipeline execution and AI commercialization:

• Clinical Acceleration: Completing patient enrollment in the CALMA Phase 2 study.

• AI Monetization: Initiating key collaborations for piloting MINT-AD (IGC's AI diagnostic platform) with academic and clinical partners.

• Pipeline Deepening: Advancing the promising IGC-M3 preclinical asset.

• Strategic Partnerships: Evaluating strategic partnerships across AI diagnostics and Alzheimer's therapeutics.

• Financial Stewardship: Strengthening operational efficiency while preserving cash runway and financial flexibility.

IGC Pharma's financial statements for the quarter ended September 30, 2025, filed on Form 10-Q, are available on www.sec.gov.

About IGC Pharma (dba IGC):

IGC Pharma (NYSE American: IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With a complete patent portfolio and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.

Forward-Looking Statements:

This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

Contact Information:

Rosalyn Christian / John Nesbett

IMS Investor Relations

igc@imsinvestorrelations.com

(203) 972-9200

SOURCE: IGC Pharma, Inc.

View the original press release on ACCESS Newswire

IGC 81's phase two trial for Alzheimer's agitation surpassed 50% enrollment, with accelerated recruitment and expansion to 35 sites in the U.S. and Canada. Strategic divestment improved financials, and the AI-based MINT-AD platform advanced to the semifinals for a $1M research prize.

Based on IGC Pharma, Inc. [IGC] Q2 2026 Audio Transcript — Nov. 17 2025

IGC 81's phase two CALMA trial for Alzheimer's agitation surpassed 50% enrollment, with completion targeted for the first half of next year and expansion to 35 sites in the U.S. and Canada. Strategic divestment improved financials, and the MINT-AD AI platform advanced to the semifinals for a $1 million research prize.

Based on IGC Pharma, Inc. [IGC] Q2 2026 Audio Transcript — Nov. 17 2025

Revenue declined year-over-year as focus shifted to clinical development and AI integration, while a key asset sale improved liquidity and reduced cash outflows. The company advanced its Alzheimer's clinical trial and AI platform, raised new equity, and extended its credit facility.

Original document: IGC Pharma, Inc. [IGC] SEC 10-Q Quarterly Report — Nov. 17 2025